Vanda Pharmaceuticals stock rises after FDA lifts partial clinical hold

Investing.com -- SoFi Technologies (NASDAQ:SOFI) stock fell 5% in after-hours trading Thursday after the company announced a $1.5 billion public offering of common stock.

The fintech company said all shares in the offering will be sold by SoFi, and it plans to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares offered.

SoFi intends to use the net proceeds from the offering for general corporate purposes, including enhancing its capital position, increasing optionality, enabling more efficient capital management, and funding incremental growth and business opportunities.

The announcement comes as SoFi continues to expand its financial services platform, which includes lending, banking, and investment products. The company has been working to strengthen its financial position amid a competitive landscape in the digital banking sector.

This capital raise could provide SoFi with additional resources to pursue its growth strategy, though the stock issuance may lead to dilution for existing shareholders, which likely contributed to the negative market reaction in after-hours trading.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Investing.com – Russia stocks were higher after the close on Thursday, as gains in the Power, Telecoms and Mining sectors led shares higher.

At the close in Moscow, the MOEX Russia Index rose 0.20%.

The best performers of the session on the MOEX Russia Index were VK Company Ltd (MCX:VKCO), which rose 5.28% or 14.40 points to trade at 286.90 at the close. Meanwhile, ROSSETI PJSC (MCX:FEES) unchanged 4.02% or 0.00 points to end at 0.07 and OZON (MCX:OZON) was up 3.90% or 149.50 points to 3,985.50 in late trade.

The worst performers of the session were MMC NORILSK NICKEL PJSC (MCX:GMKN), which fell 0.78% or 1.00 points to trade at 128.90 at the close. Sberbank Rossii PJSC (MCX:SBER) declined 0.35% or 1.06 points to end at 301.79 and PhosAgro PJSC (MCX:PHOR) was down 0.33% or 22.00 points to 6,564.00.

Rising stocks outnumbered declining ones on the Moscow Stock Exchange by 163 to 74 and 15 ended unchanged.

The Russian Volatility Index – RVI, which measures the implied volatility of MOEX Russia Index options, was down 2.50% to 32.75 a new 1-month low.

Gold Futures for February delivery was up 0.14% or 5.85 to $4,238.35 a troy ounce. Elsewhere in commodities trading, Crude oil for delivery in January rose 1.37% or 0.81 to hit $59.76 a barrel, while the February Brent oil contract rose 1.07% or 0.67 to trade at $63.34 a barrel.

USD/RUB was down 0.50% to 77.21, while EUR/RUB fell 2.29% to 88.48.

The US Dollar Index Futures was up 0.23% at 99.02.

Investing.com -- Praxis Precision Medicines (NASDAQ:PRAX) stock surged 25% after the company announced its EMBOLD study evaluating relutrigine was stopped early due to positive efficacy results.

The clinical-stage biopharmaceutical company said the Data Monitoring Committee recommended halting the registrational cohort of the study, which was evaluating relutrigine for treating patients with SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs).

Praxis confirmed it has an upcoming meeting with the FDA to discuss the results and the path forward for a New Drug Application (NDA). The company will determine the timing for filing an NDA after this meeting.

"SCN2A and SCN8A DEEs are devastating conditions with extremely high mortality due to the debilitating seizure burden they impose on patients, and there are currently no approved treatment options," said Marcio Souza, president and chief executive officer of Praxis.

The company plans to present the EMBOLD topline results at the American Epilepsy Society Annual Meeting on December 6, 2025, at the Georgia World Congress Center.

In a separate announcement, Praxis revealed it successfully completed a pre-NDA meeting with the FDA regarding ulixacaltamide, its treatment for essential tremor. The company has gained alignment from the agency on the NDA content and expects to complete this submission in early 2026.

Praxis focuses on developing therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.